CME

Program Description:

Adjuvant therapy including 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) followed by weekly paclitaxel was associated with a slight but significant improvement in disease-free survival versus FAC alone in patients with high-risk, node-negative breast cancer, according to results of the first efficacy analysis presented at the 2012 Annual Meeting of the American Society of Clinical Oncology.


Continue Reading

INTENDED AUDIENCE:

Physicians, nurse practitioners, physician assistants, nurses, and other healthcare providers who manage patients with breast cancer.

Activity Objectives:

After participating in this educational activity, participants should be better able to:

  • Evaluate the role of a sequential weekly addition of paclitaxel to cytotoxic agent protocols in patients with high-risk node-negative breast cancer.
  • Identify the hematologic and nonhematologic toxicities associated with FAC and FAC-paclitaxel in high-risk node-negative breast cancer patients.

Click Next to begin the activity.